Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
40.12
-1.82 (-4.34%)
Nov 17, 2026, 3:00 PM CST

SHA:688513 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3001,3291,3481,1161,1701,023
Other Revenue
2.32.31.841.420.630.07
1,3031,3311,3501,1171,1711,023
Revenue Growth
-1.98%-1.36%20.82%-4.56%14.43%10.96%
Cost of Revenue
321.02336.21345.23226.94199.11146.32
Gross Profit
981.68995.181,005890.18971.4876.62
Selling, General & Admin
483.5517.78552.93483.43564.44528.06
Research & Development
313.24262.74262.77237.45229.99199.59
Other Operating Expenses
26.1515.9417.3717.4618.1515.75
Operating Expenses
821.25796.24836.11737.98814741.14
Operating Income
160.44198.94168.42152.2157.4135.47
Interest Expense
-2.25-2.51-3.68-3.42-2.61-0.36
Interest & Investment Income
50.3252.1127.3825.6120.6932.83
Currency Exchange Gain (Loss)
-0.42-0.420.1600.030.02
Other Non Operating Income (Expenses)
-1.83-0.10.28-0.1-0.11-0.19
EBT Excluding Unusual Items
206.25248.01192.56174.29175.41167.77
Gain (Loss) on Sale of Investments
21.0217.1314.9214.5719.9913.69
Gain (Loss) on Sale of Assets
-0.38-0.18-0.110.030.19-0.1
Other Unusual Items
35.7134.6945.2252.7666.465.56
Pretax Income
264.5299.65252.59241.64261.99246.92
Income Tax Expense
34.0726.0814.3515.0715.4714.49
Earnings From Continuing Operations
230.43273.57238.23226.57246.52232.43
Minority Interest in Earnings
42.0910.49----
Net Income
272.52284.06238.23226.57246.52232.43
Net Income to Common
272.52284.06238.23226.57246.52232.43
Net Income Growth
12.90%19.23%5.15%-8.09%6.06%30.46%
Shares Outstanding (Basic)
173174175177177176
Shares Outstanding (Diluted)
173174175177177176
Shares Change
-1.96%-0.52%-1.04%0.14%0.37%19.70%
EPS (Basic)
1.581.631.361.281.391.32
EPS (Diluted)
1.581.631.361.281.391.32
EPS Growth
15.16%19.85%6.25%-8.22%5.68%8.98%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
169.84178.66145.8299.99-187.38-122.59
Free Cash Flow Per Share
0.981.020.830.56-1.06-0.70
Dividend Per Share
0.4900.4900.4300.3950.3810.531
Dividend Growth
13.95%13.95%8.97%3.57%-28.19%159.97%
Gross Margin
75.36%74.75%74.42%79.68%82.99%85.70%
Operating Margin
12.32%14.94%12.48%13.62%13.45%13.24%
Profit Margin
20.92%21.34%17.65%20.28%21.06%22.72%
Free Cash Flow Margin
13.04%13.42%10.80%8.95%-16.01%-11.98%
EBITDA
257.53289.92251.25225.43215.75168.08
EBITDA Margin
19.77%21.78%18.62%20.18%18.43%16.43%
D&A For EBITDA
97.190.9982.8473.2358.3532.6
EBIT
160.44198.94168.42152.2157.4135.47
EBIT Margin
12.32%14.94%12.48%13.62%13.45%13.24%
Effective Tax Rate
12.88%8.70%5.68%6.24%5.90%5.87%
Revenue as Reported
1,3031,3311,3501,1171,1711,023
Advertising Expenses
----403393.56